GovChime
Notice ID: f8349f8e80c24fa68fc88088cfa48e56Combined Synopsis/Solicitation

Defibrinated Plasma from Vaccinated Subjects

Archived on June 24, 2021. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
3:00 PM UTC−04:00
Posted
June 3, 2021
Notice type
Combined Synopsis/Solicitation
Set-aside
Small Business Set Aside - Total
NAICS
325414: Biological Product (except Diagnostic) Manufacturing
Agency
Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Notice details

Office
BARDA - ASPR / DAAPPO / BARDA DCMA
Last updated
Sep 25, 2026

Identifiers

Solicitation number
75A50121R00039
Notice ID
f8349f8e80c24fa68fc88088cfa48e56

Description

The emergence of SARS-CoV-2 variant viruses has elicited a surge of requests to several clinical trial companies and investigators for access to vaccinee and convalescent sera for use in efficacy studies of COVID-19 medical countermeasures (MCMs). As these requests are expected to persist, the U.S. Government is creating a new centralized serum repository to ensure the availability of these samples for continued assessments of MCM efficacy against new and existing variant viruses and thereby lessen the burden these requests are currently placing on vaccine companies. To this end, there is an urgent need to source and convert (to serum) plasma from individuals who are COVID-19-naïve and have undergone COVID-19 vaccination under FDA-issued Emergency Use Authorization and from individuals who have been infected with SARS-CoV-2 variants of concern and interest. The purpose of this acquisition is to acquire defibrinated plasma. The successful offeror will have the capacity and operational infrastructure to convert plasma to serum (defibrinate) and subsequently aliquot, label, freeze, package, and ship the defibrinated plasma to a U.S. Government-selected storage and distribution facility. The defibrinated plasma must meet the U.S. Government’s specifications set forth in the attached Purchase Description. The Government will conduct a quality audit of the facility pre-award to ensure vendor capabilities and quality controls. See attached BARDA CSS 75A50121R00039 with Attachments.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Contracting Officer

Primary Contact

Documents

No documents available.

Lifecycle

Solicitation:75A50121R00039
  1. Combined Synopsis
  1. Combined SynopsisCurrentJun 3, 2021

    Defibrinated Plasma from Vaccinated Subjects

    Notice f8349f8e80c24fa68fc88088cfa48e56 on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75A50121R00039

Archive Date

Jun 24, 2021

Office Address

WASHINGTON, DC, 20515